CER Evidence Summit

In Obama's health care reform bill, there was a CER Provision in the Patient Protection and Affordable Care Act. This Act allocated $1.1 Billion dollars for CER research which will be overseen by the NIH (National Institute of Health.) Now with the number of CER trials being conducted by the government, Pharma needs to figure out a better way to communicate the CER evidence that is generated when a new drug is launched. Positive CER results can allow a pharmaceutical company to re-negotiate with the payor, assist in positive marketing messages, negotiate with manufacturing companies when developing prices and quality, and also assist in pricing strategies.

Top Reasons To Attend This Conference

  1. Develop a clear understanding of the role CER plays in the drug development process including post-approval
  2. Learn directly from payers on the role CER evidence has in the reimbursement process
  3. Gain strategies for managing your product when new CER evidence changes overall class efficacy and cost-effectiveness

Benefit from industry participation from:

  • BLUE CROSS BLUE SHIELD ASSOCIATION
  • BRISTOL-MYERS SQUIBB
  • ENDO PHARMACEUTICAL
  • MERCK
  • CELGENE CORPORATION
  • NOVARTIS
  • JANSSEN
  • ASTRAZENECA PLC
  • PFIZER INC.
  • AETNA
  • SANOFI-AVENTIS U.S.
  • University of CHICAGO MEDICAL CENTER
  • AMGEN
  • and many more!

Additionally, hear from Keynote Michael S Lauer, MD, FACC, FAHA, National Institute of Health regarding The NIH's Expectations for Using CER Evidence for Commercialization. 

Justify Your Trip!

If you have to first convince your boss it's worth your time and the company's money to attend this event, you're not alone. Past conferenceattendees have helped us create the following justification document thatwill let you make your case on why this is a must-attend conference for you.

Feel free to download and customize the letter below as you see fit, addingimmediate problems you'll be able to solve and long-term initiativesyou'll be able to implement. Chances are good you'll be able to do thosethings and more after the conclusion of our 2012 event!

CLICK HERE TO DOWNLOAD OUR JUSTIFICATION PROPOSAL

Who Should Attend

This conference is designed for pharmaceutical, biotechnology, specialty pharma, generics, medical devices, and life science professionals whose responsibilities include:

  • Health Economics
  • Outcome Research
  • Comparative Effectiveness Research
  • Pricing
  • Brand Access
  • Market Access
  • Commercialization
  • Payer Relationships
  • Outcomes
  • Patient-Reported Outcomes
  • Marketing (For new drug commercialization)
  • Outcomes Liaison
  • Access Solutions

And also for:

  • Comparative Effectiveness Research Organizations
  • Health Outcomes Researchers
  • Pricing and Market Access Service Providers
  • Data Analysts Consults
  • Data Management Technology Organization
  • Health Economic Consultants